Literature DB >> 16629383

RNA interference: a potential therapeutic tool for silencing splice isoforms linked to human diseases.

Rajesh K Gaur1.   

Abstract

Alternative splicing of precursor messenger RNAs (pre-mRNAs) is one of the most important sources of protein diversity in vertebrates. An estimated 35%-70% of human genes generate transcripts that are alternatively spliced, and defects in this process are linked to numerous human genetic diseases and various forms of cancer. The discovery that 21-23 nucleotide RNA duplexes, known as small interfering RNAs (siRNAs), can knockdown the homologous mRNAs in mammalian cells has revolutionized many aspects of drug discovery including down-regulation of disease-associated splicing isoforms. In addition, RNA interference (RNAi)-mediated silencing of splicing regulators has the potential to define the complex network of alternative splicing regulation and to analyze gene function. In this review, I first provide a brief introduction to mRNA splicing and its relationship to human diseases. This is followed by a brief overview of RNAi. Finally I discuss the therapeutic potential of RNAi in targeting disease-linked splicing isoforms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16629383     DOI: 10.2144/000112165

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  10 in total

1.  Alternative splicing as a therapeutic target for human diseases.

Authors:  Kenneth J Dery; Veronica Gusti; Shikha Gaur; John E Shively; Yun Yen; Rajesh K Gaur
Journal:  Methods Mol Biol       Date:  2009

Review 2.  RNAi: a potential new class of therapeutic for human genetic disease.

Authors:  Attila A Seyhan
Journal:  Hum Genet       Date:  2011-05-03       Impact factor: 4.132

3.  A Survey of Statistical Models for Reverse Engineering Gene Regulatory Networks.

Authors:  Yufei Huang; Isabel M Tienda-Luna; Yufeng Wang
Journal:  IEEE Signal Process Mag       Date:  2009-01-01       Impact factor: 12.551

4.  Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicity.

Authors:  Farnaz Yamoutpour; Vidya Bodempudi; Shay E Park; Weihong Pan; Mary Jean Mauzy; Robert A Kratzke; Arkadiusz Dudek; David A Potter; Richard A Woo; Donald M O'Rourke; Donald J Tindall; Faris Farassati
Journal:  Mol Cancer Ther       Date:  2008-11       Impact factor: 6.261

5.  A multifunctional lentiviral-based gene knockdown with concurrent rescue that controls for off-target effects of RNAi.

Authors:  Yunfeng Feng; Linghu Nie; Meghna Das Thakur; Qin Su; Zhenfen Chi; Yongliang Zhao; Gregory D Longmore
Journal:  Genomics Proteomics Bioinformatics       Date:  2010-12       Impact factor: 7.691

Review 6.  Modulating the expression of disease genes with RNA-based therapy.

Authors:  Matthew Wood; Haifang Yin; Graham McClorey
Journal:  PLoS Genet       Date:  2007-06       Impact factor: 5.917

7.  Functional characterization and identification of mouse Rad51d splice variants.

Authors:  Aaron M Gruver; Brian D Yard; Campbell McInnes; Changanamkandath Rajesh; Douglas L Pittman
Journal:  BMC Mol Biol       Date:  2009-03-27       Impact factor: 2.946

8.  Ligand-induced sequestering of branchpoint sequence allows conditional control of splicing.

Authors:  Dong-Suk Kim; Veronica Gusti; Kenneth J Dery; Rajesh K Gaur
Journal:  BMC Mol Biol       Date:  2008-02-12       Impact factor: 2.946

9.  Altered splicing of CEACAM1 in breast cancer: identification of regulatory sequences that control splicing of CEACAM1 into long or short cytoplasmic domain isoforms.

Authors:  Shikha Gaur; John E Shively; Yun Yen; Rajesh K Gaur
Journal:  Mol Cancer       Date:  2008-05-28       Impact factor: 27.401

10.  TIPMaP: a web server to establish transcript isoform profiles from reliable microarray probes.

Authors:  Neelima Chitturi; Govindkumar Balagannavar; Darshan S Chandrashekar; Sadashivam Abinaya; Vasan S Srini; Kshitish K Acharya
Journal:  BMC Genomics       Date:  2013-12-27       Impact factor: 3.969

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.